Cholangiocarcinomas (CCAs) are a highly aggressive and diverse group of malignancies of the biliary tract that currently account for 15% of all liver cancers and approximately 3% of gastrointestinal tumors. While rare, the ...
Nov 29, 2022
0
25
Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olaparib and adavosertib, if they are given in sequence rather than concurrently.
Oct 27, 2022
0
4
Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers—ATR inhibitor elimusertib and PARP inhibitor AZD5305—are safe and clinically beneficial in treating ...
Apr 11, 2022
0
4
A potential new drug candidate developed by researchers at the University of Oulu, Finland, has been granted a patent in the United States. The drug is a small molecular chemical compound that is especially suited for cancer ...
Nov 8, 2021
0
7
An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented ...
Oct 22, 2013
0
0
Malignant melanoma is a highly aggressive and notoriously chemoresistant form of cancer. In a new paper, Ohanna et al. reveal that anti-melanoma drugs may, paradoxically, induce a senescence-associated secretory profile ("secretome") ...
Jun 6, 2011
0
0
